Volume : 11, Issue : 09, September – 2024
Title:
FORMULATION AND EVALUATION OF BOSENTAN SUSTAINED RELEASE TABLETS
Authors :
Rithu Raj G*and Silas P
Abstract :
The aim of the present study was to develop sustained release formulation of Bosentan to maintain constant therapeutic levels of the drug for over 8 hrs. Various synthetic polymers were employed as polymers. Bosentan dose was fixed as 62.5 mg. Total weight of the tablet was considered as 200 mg Polymers were used in the concentration of 31.5,41.25,62.5 mg concentration. All the formulations were passed various physicochemical evaluation parameters and they were found to be within limits. And the drug and excipient compatibility studies showed that there is no interaction between the drug and polymers employed in the formulation. Whereas from the dissolution studies it was evident that the formulation F3, showed better and desired drug release pattern i.e.,98.13 respectively % in 8 hours.
Cite This Article:
Please cite this article in press Rithu Raj G et al Formulation And Evaluation Of Bosentan Sustained Release Tablets..,Indo Am. J. P. Sci, 2024; 11 (9).
Number of Downloads : 10
References:
1. James, PA.; Oparil, S.; Carter, BL.; Cushman, WC.; Dennison-Himmelfarb, C.; Handler, J.; Lackland, DT.; Lefevre, ML. Et al. (Dec 2013). “2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8)”. JAMA 311 (5): 507–20. Doi:10.1001/jama.2013.284427. PMID 24352797.
2. Lewington, S; Clarke, R; Qizilbash, N; Peto, R; Collins, R; Prospective Studies, Collaboration (Dec 14, 2002). “Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective
3. studies.”. Lancet 360 (9349):1903–13. Doi:10.1016/s0140-6736(02)11911-8.PMID 1249 3255.
4. Carretero OA, Oparil S; Oparil (January 2000). “Essential hypertension. Part I: definition and etiology”. Circulation 101 (3): 329 35. Doi:10.1161/01.CIR.101.3.329.
5. Diao, D; Wright, JM; Cundiff, DK; Gueyffier, F (Aug 15, 2012). “Pharmacotherapy for mild hypertension.”. The Cochrane database of systematic reviews 8: CD006742.doi:10.1002/14651858.CD006742.pub2. PMID 22895954.
6. Arguedas, JA; Leiva, V; Wright, JM (Oct 30, 2013). “Blood pressure targets for hypertension in people with diabetes mellitus.”. The Cochrane database of systematic reviews 10: CD008277. Doi:10.1002/14651858.cd008277.pub2. PMID 24170669.
7. Sundström, Johan; Arima, Hisatomi; Jackson, Rod; Turnbull, Fiona; Rahimi, Kazem;
8. Chalmers, John; Woodward, Mark; Neal, Bruce (February 2015). “Effects of Blood Pressure Reduction in Mild Hypertension”. Annals of Internal Medicine 162: 184–91.doi:10.7326/M14-0773. PMID 25531552.
9. Fisher ND, Williams GH (2005). “Hypertensive vascular disease”. In Kasper DL, Braunwald E, Fauci AS et al. Harrison’s Principles of Internal Medicine (16th ed.). New York, NY: mcgraw-Hill. Pp. 1463–81. ISBN 0-07-139140-1.
10. Marshall, IJ; Wolfe, CD; mckevitt, C (Jul 9, 2012). “Lay perspectives on hypertension and drug adherence: systematic review of qualitative research”. BMJ (Clinical research ed.) 345: e3953. Doi:10.1136/bmj.e3953. PMC 3392078. PMID 22777025.
11. Pennsylvania Patient Safety Authority (December 2004), “Drug name suffix confusion is a common source of errors”, PA PSRS Patient Saf Advis 1(4): 17–18.
12. Jump up^ http://www.netdoctor.co.uk/medicines/100004842.html
13. Jump up^ Vranić, E; Uzunović, A (August 2009). “Influence of splitting on dissolution properties of metoprolol tablets.”. Bosnian journal of basic medical sciences / Udruzenje basicnih medicinskih znanosti = Association of Basic Medical Sciences 9 (3): 245–9. PMID 19754482.